Brought to you by 
InteKrin gets global rights to Amgen's compound for diabetes
02 Feb 2007
Executive Summary
InteKrin Therapeutics (developing drugs for cancer, immunology, and metabolic conditions) has licensed exclusive worldwide development and marketing rights to Amgen's AMG131 (renamed INT131).
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
InteKrin gets global rights to Amgen's compound for diabetes
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice